Agios Pharmaceuticals, Inc.
37.00USD
-0.1900 (-0.51%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on AGIO.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$1.23▲ | -$1.48 | 0 | 3 |
| Next quarter | -$1.14▲ | -$1.4 | 1 | 1 |
| Current year | -$5.74▲ | -$6.21 | 0 | 3 |
| Next year | -$3.77▲ | -$4.65 | 0 | 3 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$1.67 | -$1.69 | -0.02 (-1.5%) |
| 2026-03-31 | -$1.79 | -$1.69 | +0.10 (+5.7%) |
| 2025-12-31 | -$1.95 | -$1.85 | +0.09 (+4.9%) |
| 2025-09-30 | -$1.9 | -$1.78 | +0.12 (+6.5%) |
142 ratings from 27 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Truist Securities | Maintained | Buy | $39 $37 | Oct 7, 2026 |
| B of A Securities | Maintained | Buy | $46 $50 | Sep 21, 2026 |
| JP Morgan | Maintained | Neutral | $31 $34 | Aug 7, 2026 |
| Citigroup | Maintained | Buy | $46 $52 | Jul 31, 2026 |
| Truist Securities | Maintained | Buy | $41 $39 | Jul 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $52 $55 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $54 $52 | Jul 21, 2026 |
| RBC Capital | Maintained | Sector Perform | $28 $32 | Jul 7, 2026 |
| Truist Securities | Maintained | Buy | $36 $41 | Jul 7, 2026 |
| B of A Securities | Maintained | Buy | $40 $46 | Jul 7, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $54 | Jun 15, 2026 |
| JP Morgan | Maintained | Neutral | $36 $31 | Jun 11, 2026 |
| B of A Securities | Maintained | Buy | $41 $40 | May 29, 2026 |
| Truist Securities | Maintained | Buy | $39 $36 | Apr 30, 2026 |
| B of A Securities | Maintained | Buy | $44 $41 | Apr 21, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $65 $50 | Apr 20, 2026 |
| JP Morgan | Maintained | Neutral | $31 $36 | Apr 6, 2026 |
| Goldman Sachs | Maintained | Neutral | $28 $32 | Apr 1, 2026 |
| Citigroup | Maintained | Buy | $38 $46 | Mar 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $62 $65 | Feb 12, 2026 |
| JP Morgan | Maintained | Neutral | $20 $25 | Jan 6, 2026 |
| Leerink Partners | Maintained | Outperform | $34 $40 | Dec 26, 2025 |
| Truist Securities | Maintained | Buy | $32 $38 | Dec 24, 2025 |
| B of A Securities | Maintained | Buy | $32 $34 | Dec 24, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $48 $62 | Dec 24, 2025 |
137 filings from 17 insiders · 19 buy / 2 sell over 6m
Officers and directors of AGIO, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gheuens SarahOfficer, Chief Medical Officer | ExerciseStock options (right to buy) | 500 | — | — | Oct 22, 2026 |
| Gheuens SarahOfficer, Chief Medical Officer | Sell | 500 | $37.52 | $19k | Oct 22, 2026 |
| Gheuens SarahOfficer, Chief Medical Officer | Exercise | 500 | $25.01 | $13k | Oct 22, 2026 |
| Gheuens SarahOfficer, Chief Medical Officer | ExerciseStock options (right to buy) | 1.5k | — | — | Oct 21, 2026 |
| Gheuens SarahOfficer, Chief Medical Officer | Sell | 1.5k | $37.53 | $56k | Oct 21, 2026 |
| Gheuens SarahOfficer, Chief Medical Officer | Exercise | 1.5k | $25.01 | $37k | Oct 21, 2026 |
| GHEUENS SARAHOfficer | Sell | 30.0k | $30.48 | $914k | Aug 4, 2026 |
| BACKSTROM JAY TDirector | Grant | 1.4k | — | — | Jul 8, 2026 |
| BACKSTROM JAY TDirector | Exercise | 1.4k | $42.76 | $62k | Jul 8, 2026 |
| GHEUENS SARAHOfficer | Other | 8.4k | — | — | Jul 1, 2026 |
| GHEUENS SARAHOfficer | Sell | 4.0k | $37.56 | $151k | Jul 1, 2026 |
| FOSTER-CHEEK KAYE IDirector | Other | 2.8k | — | — | Jun 18, 2026 |
| FOUSE JACQUALYN A.Director | Other | 2.8k | — | — | Jun 18, 2026 |
| GOFF BRIANChief Executive Officer | Exercise | 39.0k | $34.16 | $1.33M | Jun 18, 2026 |
| SMITH CYNTHIADirector | Other | 2.8k | — | — | Jun 18, 2026 |
| CAPELLO JEFFREY DDirector | Other | 2.8k | — | — | Jun 18, 2026 |
| HO MAYKINDirector | Other | 2.8k | — | — | Jun 18, 2026 |
| SCADDEN DAVID T.Director | Other | 2.8k | — | — | Jun 18, 2026 |
| BURNS JAMES WILLIAMOfficer | Exercise | 3.0k | $34.16 | $102k | Jun 18, 2026 |
| MILANOVA TSVETAOfficer | Exercise | 3.0k | $34.16 | $102k | Jun 18, 2026 |
No analyst notes on AGIO yet.
Members whose judged calls on AGIO have played out most reliably.
No settled calls on AGIO yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
8 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 7 | 3 | 0 | 0 | Buy2.30 |
| 1 mo ago | 0 | 7 | 3 | 0 | 0 | Buy2.30 |
| 2 mo ago | 0 | 7 | 3 | 0 | 0 | Buy2.30 |
| 3 mo ago | 0 | 7 | 3 | 0 | 0 | Buy2.30 |